Published in

Elsevier, The Lancet Oncology, 1(18), p. 31-41

DOI: 10.1016/s1470-2045(16)30624-6

Links

Tools

Export citation

Search in Google Scholar

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Journal article published in 2017 by Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott N. Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal E. Ready, David E. Gerber, Laura Q. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie ORCID, William J. Geese, Shruti Agrawal, Tina C. Young and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO